The present invention relates to an improved process for the preparation of valsartan Formula I and its pharmaceutically acceptable salts. Fig.

The present invention relates to an improved process for the manufacture of Olmesartan and its pharmaceutically acceptable salts and esters thereof, as active ingredients of a medicament for the treatment of hypertension and related diseases and conditions. Olmesartan medoxomil, is chemically described as Olmesarta...

The invention relates to a novel process for the preparation of (S,S)-2, 8-Diazabicyclo(4, 3, 0) Nonane of Formula I Which is useful as an intermediate in the preparation of Moxifloxacin.

The present invention is directed to a process for the preparation of enantiomerically enriched β-amino acid derivatives which are important chiral building blocks and intermediates in pharmaceuticals. More specifically, the invention pertains to a novel process for practically convenient and economically producing ...

The invention relates to an improved process for the purification of trityl candesartan of formula I Formula I which is useful as an Intermediate in the preparation of Candesartan Cilexetil.

The invention relates to a novel process for the preparation of (S)-Methyl-2-amino-2-(2-chlorophenyl) acetate hydrochloride of Formula I which is useful as an Intermediate in the preparation of Clopidogrel bisulphate.

The invention relates to a novel process for the preparation of (R)-5-(2-Aminopropyl)-2-methoxybenzenesulfonamide and its acid addition salts. Formula I is a useful intermediate in the preparation of Tamsulosin.

The invention relates to an improved process for the preparation of 2-Cyano-4"-formyl biphenyl of Formula I which is useful as an Intermediate in the preparation of Valsartan.

The present invention relates to a novel process for the preparation of 2-methyl-4H-3-thia-4, 9-diazabenzo[/]azulen-10-ylamine hydrochloride of Formula I, an useful intermediate in the preparation of Olanzapine.

The invention  relates to a novel process for the preparation of (4S)-6-chloro-4-(cyclopropylcthynyl)-1.4-dihydro-4-(trifluoromethyl)-2H-3,l-benzoxazin-2-one (Effavirenz) of Formula I, are useful as human immunodeficiency (HIV) reverse transcriptase inhibitors.

The present invention relates to an improved process for the preparation of Blonanserin. Blonanserin, 2-(4-ethylpiperazin-1 -yl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydrocycloocta[b] pyridine is an atypical antipsychotic. Blonanserin exhibit potent binding property to serotonin (S2) and dopamine (D2) receptors, the...

The invention relates to an improved process for the preparation of N-(1-Oxopentyl)-N-[[2"-(1H-tetrazol-5-yl) 11,1"-biphenyl [-4-yl ]methyl ]-L-valine (i.e Valsartan) which is used as an anti hypertensive drug. The invention has the advantage of reduced number of isolated steps. The process of the present invention ...